Pancreatic Cancer Research

ResearcherErasmus MCActive in the last 2 years

Songul Kucukcelebi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0008-5029-1519; OpenAlex author ID A5014878776. Sources: ClinicalTrials.gov.

Their work

Papers
3
Trials
1
Grants
0
Labs led
0
Collaborators
11
Papers, trials and grants by year

2024: 1 paper, 1 trial · 2025: 1 paper · 2026: 1 paper

Papers 3

  1. CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic Targeting. Co-author DOI 10.3390/cancers18111743↗
  2. REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer. Co-author DOI 10.1038/s41467-025-66092-1↗
  3. Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell-Mediated T-Cell Responses. Co-author DOI 10.1158/1078-0432.ccr-23-4085↗

Trials 1

  1. Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Th… Study director NCT05927142↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Casper H.J. van Eijck · 3 shared papers, 1 shared trial, 2024–2026 · strength 1.30
  2. Casper W.F. van Eijck · 3 shared papers, 2024–2026 · strength 0.76
  3. Marjolein Y.V. Homs · 1 shared paper, 1 shared trial, 2024–2025 · strength 0.72
  4. Judith de Vos‐Geelen · 2 shared papers, 2025–2026 · strength 0.54
  5. Aniek E. van Diepen · 2 shared papers, 2025–2026 · strength 0.54
  6. Marcella Willemsen · 2 shared papers, 2024–2025 · strength 0.40
  7. Hassana el Haddaoui · 1 shared paper, 2024 · strength 0.22
  8. Dana A. M. Mustafa · 1 shared paper, 2024 · strength 0.22
  9. Michail Doukas · 1 shared paper, 2025 · strength 0.18
  10. Freek R. van ‘t Land · 1 shared paper, 2025 · strength 0.18
  11. Ferry A.L.M. Eskens · 1 shared paper, 2025 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.